News
-
-
PRESS RELEASE
Dr. Michael Jewett Joins Theralase(R) to Help Complete Enrollment in the Phase II Non-Muscle Invasive Bladder Cancer Clinical Study
Theralase® Technologies Inc. announces the addition of Dr. Michael Jewett as an independent consultant to assist in completing enrollment of patients in the Phase II NMIBC CIS clinical study. Dr. Jewett's expertise will help achieve regulatory approval -
PRESS RELEASE
Theralase(R) Closes $CAN 1.2 Million Non-Brokered Private Placement
Theralase Technologies Inc. has closed a non-brokered private placement offering of units, raising approximately $CAN 1,200,000 for cancer research and development. The company plans to use the funds for clinical study, preclinical research, and general corporate purposes -
PRESS RELEASE
Theralase(R) Provides Update on Phase II Bladder Cancer Clinical Study
Theralase Technologies Inc. provides an update on its Phase II Non-Muscle Invasive Bladder Cancer clinical study, demonstrating favorable interim clinical data that exceeds the International Bladder Cancer Group's guidelines. With 63 patients treated to date, the study shows promising results, potentially leading to Break Through Designation and Accelerated Approval. The Company plans to complete enrollment and delivery of the primary Study II Treatment for all patients in 2024, with potential Health Canada and FDA approval expected by 2026 / 2027. -
-
-
-
PRESS RELEASE
Theralase(R) Announces Brokered LIFE Financing
-
-
-
Allied Universal Event Services Professional Winner of Golden State Warriors’ Champion Spotlight Annual Starting 5
-
Viking Capital Announces Closing of Latest 252 Unit Acquisition in Austin - San Antonio Corridor
-
Assays Confirm High-Grade Tarcoola Open Pit Extensions
-
Seismic Survey Reveals Tarcoola Goldfield Architecture
-
OTCQB Trading Secured with DTCC Registration Approval
-
Turkiye Garanti Bankasi A.S.: Prospectus – Summary
-
Turkiye Garanti Bankasi A.S.: Prospectus – Capital Markets Instrument Note
-
EQS-Adhoc: United Internet AG: Non-scheduled, non-cash impairment on Tele Columbus investment
-
Shelly Group: Successful placement of shares with participation of BIT Capital for targeted increase in free float
-
Extraordinary General Meeting of 12 June 2024 - All proposals of the Board of Directors were confirmed by the General Meeting
-
Monthly disclosure of the total number of shares and voting rights - 31/05/2024
-
Combined General Meeting, June 13, 2024
-
Europorte and Kerlink revolutionize freight by launching Track Value, the first logistics application using Kinéis IoT space connectivity
-
AXA: Information relating to the number of voting rights and shares making up the share capital on 31/05/2024
-
Declaration of voting rights at the end of May 2024